|
Oct 1
|
SciSparc receives FDA approval for trial for Tourette syndrome therapy
|
|
Sep 30
|
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
|
|
Aug 29
|
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
|
|
Aug 28
|
SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
|
|
Aug 26
|
SciSparc secures final approval in Israel to start Tourette’s Syndrome trial
|
|
Aug 26
|
SciSparc seeks FDA IND clearance for Phase IIb Tourette Syndrome treatment trial
|
|
Mar 21
|
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
|
|
Mar 18
|
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
|
|
Mar 14
|
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
|
|
Jan 29
|
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
|
|
Jan 24
|
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
|
|
Dec 7
|
SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel
|
|
Dec 1
|
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial
|
|
Nov 28
|
SciSparc Adopts Limited Duration Shareholder Rights Plan
|
|
Nov 28
|
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
|
|
Nov 27
|
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
|
|
Sep 7
|
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
|
|
Sep 7
|
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
|